Abstract: SPD754 susceptibility was reduced 1.2- to 2.2-fold against isolates resistant to zidovudine (
M41L,
T215Y/F, plus a median of three additional nucleoside analogue mutations [NAMs]) and/or lamivudine (
M184V) and was reduced 1.3- to 2.8-fold against isolates resistant to abacavir (
L74V,
Y115F, and
M184V plus one other NAM) or stavudine (
V75T/M,
M41L,
T215F/Y, and four other NAMs).